Their epigenetic silencing (H3K9me3 labelling) inhibited EWS-FLI1 binding to the SOX2 enhancer (SRY-box transcription factor 2), thereby reducing its expression and altering tumor growth in vivo (Boulay et al., 2018). Here, SOX2 is linked to neoplasm.